ValuEngine Upgrades Twist Bioscience (NASDAQ:TWST) to “Buy”

Twist Bioscience (NASDAQ:TWST) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday, ValuEngine reports.

Separately, Zacks Investment Research lowered Twist Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, October 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $26.55.

TWST stock traded up $0.58 during trading on Thursday, hitting $21.86. 123,000 shares of the company traded hands, compared to its average volume of 178,785. Twist Bioscience has a 1 year low of $13.99 and a 1 year high of $35.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.96 and a current ratio of 7.18. The firm has a market capitalization of $699.53 million and a PE ratio of -0.86. The company has a 50-day moving average of $23.31 and a 200-day moving average of $26.69.

In related news, SVP Mark Daniels sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $29.90, for a total transaction of $44,850.00. Also, SVP Patrick Weiss sold 14,730 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $30.66, for a total value of $451,621.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 281,143 shares of company stock valued at $7,532,938. 29.40% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of TWST. Elkfork Partners LLC boosted its stake in Twist Bioscience by 100.0% during the 2nd quarter. Elkfork Partners LLC now owns 924 shares of the company’s stock valued at $27,000 after purchasing an additional 462 shares during the last quarter. Meadow Creek Investment Management LLC boosted its stake in Twist Bioscience by 100.0% during the 2nd quarter. Meadow Creek Investment Management LLC now owns 1,176 shares of the company’s stock valued at $34,000 after purchasing an additional 588 shares during the last quarter. Glen Harbor Capital Management LLC boosted its stake in Twist Bioscience by 100.0% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,428 shares of the company’s stock valued at $41,000 after purchasing an additional 714 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Twist Bioscience by 536.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,484 shares of the company’s stock valued at $43,000 after purchasing an additional 1,251 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in Twist Bioscience by 87,550.0% during the 2nd quarter. Bank of Montreal Can now owns 1,753 shares of the company’s stock valued at $51,000 after purchasing an additional 1,751 shares during the last quarter. 42.69% of the stock is owned by institutional investors.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

See Also: What is the QQQ ETF?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.